Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis
Authors:
- Ana Luíza Rocha Soares MenegatAMAna Luíza Rocha Soares Menegat
- Brenda Luana Rocha Soares MenegatBMBrenda Luana Rocha Soares Menegat
- Luana Diniz Guerra BrazLBLuana Diniz Guerra Braz
- Maria Victória Ferreira PiccoliMPMaria Victória Ferreira Piccoli
- Thiago Gorayeb RebeloTRThiago Gorayeb Rebelo
- Francisco Cezar Aquino de MoraesFrancisco Cezar Aquino de Moraes
- 22 January 2026
- journal article
- review article
- Published by Taylor & Francis in Immunotherapy
- Vol. 18 (2) , 139-155
Abstract
1. Urothelial carcinoma (UC) is a heterogeneous group of malignancies arising from the urothelial lining of the urinary tract, with bladder cancer accounting for approximately 90% of cases, followe...Keywords
This publication has 61 references indexed in Scilit:
- SEOM–SOGUG clinical guideline for urothelial cancer (2025)Clinical and Translational Oncology, 2025
- The Future of Cancer Therapy: Nanomaterials and Tumor MicroenvironmentiMetaMed, 2025
- The microbiome in canceriMeta, 2025
- Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle‐invasive bladder cancer: A multi‐center, single‐arm, phase 2 studyCancer Medicine, 2023
- Statistical considerations in clinical trial design with event‐free survival as the primary efficacy endpointPharmaceutical Statistics, 2021
- Bladder CancerJAMA, 2020
- Assessing risk of bias due to missing results in a synthesis2019
- A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladderCancer, 2008
- A graphical method for exploring heterogeneity in meta‐analyses: application to a meta‐analysis of 65 trialsStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986